MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma

References

1. 1.↵
   1. Ostrom QT,
   2. Gittleman H,
   3. Truitt G, et al

   . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015. Neuro Oncol 2018;20:iv1–86 doi:10.1093/neuonc/noy131 pmid:30445539

   CrossRefPubMed
2. 2.↵
   1. Hassan H,
   2. Pinches A,
   3. Picton SV, et al

   . Survival rates and prognostic predictors of high-grade brain stem gliomas in childhood: a systematic review and meta-analysis. J Neurooncol 2017;135:13–20 doi:10.1007/s11060-017-2546-1 pmid:28681244

   CrossRefPubMed
3. 3.↵
   1. Castel D,
   2. Philippe C,
   3. Calmon R, et al

   . Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 2015;130:815–27 doi:10.1007/s00401-015-1478-0 pmid:26399631

   CrossRefPubMed
4. 4.↵
   1. Pope WB,
   2. Chen JH,
   3. Dong J, et al

   . Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology 2008;249:268–77 doi:10.1148/radiol.2491072000 pmid:18796682

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Gutman DA,
   2. Cooper LA,
   3. Hwang SN, et al

   . MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 2013;267:560–69 doi:10.1148/radiol.13120118 pmid:23392431

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Nowak J,
   2. Nemes K,
   3. Hohm A, et al

   . Magnetic resonance imaging surrogates of molecular subgroups in atypical teratoid/rhabdoid tumor. Neuro Oncol 2018;20:1672–79 doi:10.1093/neuonc/noy111 pmid:30010851

   CrossRefPubMed
7. 7.↵
   1. Perreault S,
   2. Ramaswamy V,
   3. Achrol AS, et al

   . MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol 2014;35:1263–69 doi:10.3174/ajnr.A3990 pmid:24831600

   Abstract/FREE Full Text
8. 8.↵
   1. Kieran MW,
   2. Goumnerova LC,
   3. Prados M, et al

   . Biopsy for diffuse intrinsic pontine glioma: a reappraisal. J Neurosurg Pediatr 2016;18:390–91 doi:10.3171/2015.6.PEDS15374 pmid:27153377

   CrossRefPubMed
9. 9.↵
   1. Jansen MH,
   2. Veldhuijzen van Zanten SE,
   3. Sanchez Aliaga E, et al

   . Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncol 2015;17:160–66 doi:10.1093/neuonc/nou104 pmid:24903904

   CrossRefPubMed
10. 10.↵
    1. Hoffman LM,
    2. Veldhuijzen van Zanten SE,
    3. Colditz N, et al

    . Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): A Collaborative Report from the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol 2018;36:1963–72 doi:10.1200/JCO.2017.75.9308 pmid:29746225

    CrossRefPubMed
11. 11.↵
    1. Chen HJ,
    2. Panigrahy A,
    3. Dhall G, et al

    . Apparent diffusion and fractional anisotropy of diffuse intrinsic brain stem gliomas. AJNR Am J Neuroradiol 2010;31:1879–85 doi:10.3174/ajnr.A2179 pmid:20595371

    Abstract/FREE Full Text
12. 12.↵
    1. Poussaint TY,
    2. Vajapeyam S,
    3. Ricci KI, et al

    . Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol 2016;18:725–34 doi:10.1093/neuonc/nov256 pmid:26487690

    CrossRefPubMed
13. 13.↵
    1. Gupta N,
    2. Goumnerova LC,
    3. Manley P, et al

    . Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol 2018;20:1547–55 doi:10.1093/neuonc/noy070 pmid:29741745

    CrossRefPubMed
14. 14.↵
    1. Fischbein NJ,
    2. Prados MD,
    3. Wara W, et al

    . Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome. Pediatr Neurosurg 1996;24:9–23 doi:10.1159/000121010 pmid:8817611

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Jenkinson M,
    2. Beckmann CF,
    3. Behrens TE, et al

    . FSL. Neuroimage 2012;62:782–90 doi:10.1016/j.neuroimage.2011.09.015 pmid:21979382

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Schindelin J,
    2. Arganda-Carreras I,
    3. Frise E, et al

    . Fiji: an open-source platform for biological-image analysis. Nat Methods 2012;9:676–82 doi:10.1038/nmeth.2019 pmid:22743772

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Benjamini Y,
    2. Hochberg Y

    . Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B (Methodological) 1995;57:289–300 doi:10.1111/j.2517-6161.1995.tb02031.x

    CrossRef
18. 18.↵
    1. Poussaint TY,
    2. Kocak M,
    3. Vajapeyam S, et al

    . MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). Neuro Oncol 2011;13:417–27 doi:10.1093/neuonc/noq200 pmid:21297126

    CrossRefPubMed
19. 19.↵
    1. Infinger LK,
    2. Stevenson CB

    . Re-examining the need for tissue diagnosis in pediatric diffuse intrinsic pontine gliomas: a review. Curr Neuropharmacol 2017;15:129–33 doi:10.2174/1570159x14666160425114024 pmid:27109746

    CrossRefPubMed
20. 20.↵
    1. Khuong-Quang DA,
    2. Buczkowicz P,
    3. Rakopoulos P, et al

    . K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 2012;124:439–47 doi:10.1007/s00401-012-0998-0 pmid:22661320

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Buczkowicz P,
    2. Bartels U,
    3. Bouffet E, et al

    . Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol 2014;128:573–81 doi:10.1007/s00401-014-1319-6 pmid:25047029

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Louis DN,
    2. Perry A,
    3. Reifenberger G, et al

    . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20 doi:10.1007/s00401-016-1545-1 pmid:27157931

    CrossRefPubMed
23. 23.↵
    1. Yan H,
    2. Parsons DW,
    3. Jin G, et al

    . IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–73 doi:10.1056/NEJMoa0808710 pmid:19228619

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Goya-Outi JC,
    2. Orlhac R,
    3. Philippe F, et al

    . Can structural MRI radiomics predict DIPG histone H3 mutation and patient overall survival at diagnosis time? In: Proceedings of the Institute of Electrical and Electronics Engineers Engineering in Medicine and Biology Society International Conference on Biomedical & Health Informatics (BHI’19), Chicago, Illinois. May 19–22, 2019: 1–4
25. 25.↵
    1. Goya-Outi J,
    2. Orlhac F,
    3. Calmon R, et al

    . Computation of reliable textural indices from multimodal brain MRI: suggestions based on a study of patients with diffuse intrinsic pontine glioma. Phys Med Biol 2018;63:105003 doi:10.1088/1361-6560/aabd21 pmid:29633962

    CrossRefPubMed
26. 26.↵
    1. Lober RM,
    2. Cho YJ,
    3. Tang Y, et al

    . Diffusion-weighted MRI derived apparent diffusion coefficient identifies prognostically distinct subgroups of pediatric diffuse intrinsic pontine glioma. J Neurooncol 2014;117:175–82 doi:10.1007/s11060-014-1375-8 pmid:24522717

    CrossRefPubMed
27. 27.↵
    1. Zukotynski KA,
    2. Vajapeyam S,
    3. Fahey FH, et al

    . Correlation of (18)F-FDG PET and MRI apparent diffusion coefficient histogram metrics with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med 2017;58:1264–69 doi:10.2967/jnumed.116.185389 pmid:28360212

    Abstract/FREE Full Text
28. 28.↵
    1. Lobel U,
    2. Sedlacik J,
    3. Reddick WE, et al

    . Quantitative diffusion-weighted and dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging analysis of T2 hypointense lesion components in pediatric diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol 2011;32:315–22 doi:10.3174/ajnr.A2277 pmid:21087935

    Abstract/FREE Full Text
29. 29.↵
    1. Nowosielski M,
    2. Recheis W,
    3. Goebel G, et al

    . ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology 2011;53:291–302 doi:10.1007/s00234-010-0808-0 pmid:21125399

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Aboian MS,
    2. Tong E,
    3. Solomon DA, et al

    . Diffusion characteristics of pediatric diffuse midline gliomas with histone H3-K27M mutation using apparent diffusion coefficient histogram analysis. AJNR Am J Neuroradiol 2019;40:1804–10 doi:10.3174/ajnr.A6302 pmid:31694820

    Abstract/FREE Full Text
31. 31.↵
    1. Chen H,
    2. Hu W,
    3. He H, et al

    . Noninvasive assessment of H3 K27M mutational status in diffuse midline gliomas by using apparent diffusion coefficient measurements. Eur J Radiol 2019;114:152–59 doi:10.1016/j.ejrad.2019.03.006 pmid:31005167

    CrossRefPubMed
32. 32.↵
    1. Bailey S,
    2. Howman A,
    3. Wheatley K, et al

    . Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy: results of a United Kingdom phase II trial (CNS 2007 04). Eur J Cancer 2013;49:3856–62 doi:10.1016/j.ejca.2013.08.006 pmid:24011536

    CrossRefPubMed
33. 33.↵
    1. Aboian MS,
    2. Solomon DA,
    3. Felton E, et al

    . Imaging characteristics of pediatric diffuse midline gliomas with histone H3 K27M mutation. AJNR Am J Neuroradiol 2017;38:795–800 doi:10.3174/ajnr.A5076 pmid:28183840

    Abstract/FREE Full Text